Skip to main content

Table 2 Reasons leading to DTG/3TC discontinuation

From: Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Reason

Number

Death

Neoplastic disease

End-stage liver disease

Myocardial infarction

Sepsis

Unknown case

11

6

2

1

1

1

Adverse events

Weight gain

Insomnia/neurological symptoms

Mialgia

Other

13

3

5

3

2

Drug unrelated causes

Lost to follow-up

Patient’s decision

Moved to other center

Anti-neoplastic therapy

20

10

6

3

1

Back to triple drug regimen

Poor adherence

Not reported

4

2

2